Suppr超能文献

顺铂、阿霉素和丝裂霉素C联合化疗(PAM)治疗非小细胞肺癌

[Combination chemotherapy with cis-platinum, adriamycin and mitomycin C (PAM) in the treatment of non-small cell carcinoma of the lung].

作者信息

Nakano H, Kurihara M, Saito R, Takise A, Tsuchiya S, Minato K, Takehara K, Saruya T, Kuwabara H, Fueki R

出版信息

Gan To Kagaku Ryoho. 1986 Jun;13(6):2123-7.

PMID:3013099
Abstract

Twenty-three patients with inoperable non-small cell lung cancer were treated with a combination chemotherapy of CDDP 100 mg/m2, ADM 30 mg/m2 and MMC 8 mg/m2 (PAM). Ten cases were adenocarcinoma, 9 cases were squamous cell carcinoma and 4 cases were large cell carcinoma. In 21 evaluable cases, partial response was obtained in 47.6%. (The response rates were 40.0% in patients with adenocarcinoma, 50.0% in those with squamous cell carcinoma and 66.7% in those with large cell carcinoma.) Leukocytopenia of less than 4,000/mm3 occurred in 100% of cases, thrombocytopenia of less than 100,000/mm3 occurred in 81.0%, and anemia(fall in hemoglobin over 2.0 g/dl) occurred in 66.7%. A transient elevation of Cr (over 1.5 mg/dl) and/or BUN (over 30 mg/dl) was observed in 23.8%. Nausea and vomiting occurred in almost all patients. No death occurred due to toxicity of PAM. These results demonstrate that PAM is an effective combination chemotherapy in patients with non-small cell carcinoma of the lung.

摘要

23例无法手术的非小细胞肺癌患者接受了顺铂100mg/m²、阿霉素30mg/m²和丝裂霉素8mg/m²(丝裂霉素)的联合化疗。腺癌10例,鳞癌9例,大细胞癌4例。在21例可评估病例中,部分缓解率为47.6%。(腺癌患者的缓解率为40.0%,鳞癌患者为50.0%,大细胞癌患者为66.7%。)100%的病例出现白细胞减少至低于4000/mm³,81.0%的病例出现血小板减少至低于100000/mm³,66.7%的病例出现贫血(血红蛋白下降超过2.0g/dl)。23.8%的患者观察到肌酐(超过1.5mg/dl)和/或尿素氮(超过30mg/dl)短暂升高。几乎所有患者都出现恶心和呕吐。未发生因丝裂霉素毒性导致的死亡。这些结果表明,丝裂霉素对非小细胞肺癌患者是一种有效的联合化疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验